List of Excipients in Branded Drug DUETACT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Takeda Pharmaceuticals America Inc	DUETACT	pioglitazone and glimepiride	64764-302	CELLULOSE, MICROCRYSTALLINE
Takeda Pharmaceuticals America Inc	DUETACT	pioglitazone and glimepiride	64764-302	CROSCARMELLOSE SODIUM
Takeda Pharmaceuticals America Inc	DUETACT	pioglitazone and glimepiride	64764-302	HYDROXYPROPYL CELLULOSE
Takeda Pharmaceuticals America Inc	DUETACT	pioglitazone and glimepiride	64764-302	LACTOSE MONOHYDRATE

Last updated: August 4, 2026

Duetact is an immediate-release fixed-dose combination of pioglitazone hydrochloride and glimepiride for adults with type 2 diabetes. Its excipient platform is conventional, low-cost, and suitable for generic development. The strongest commercial opportunities are authorized or ANDA generic supply, excipient cost optimization, dual-strength manufacturing, and differentiated adherence products. The main barriers are bioequivalence, dose-ratio limitations, pioglitazone safety concerns, and declining demand for older diabetes therapies.

Duetact Excipient Strategy and Commercial Opportunities

What is Duetact and how is it formulated?

Duetact combines two oral antihyperglycemic agents:

Attribute	Duetact profile
Active ingredients	Pioglitazone hydrochloride and glimepiride
Dosage form	Immediate-release oral tablet
Available strengths	30 mg/2 mg and 30 mg/4 mg
Original sponsor	Takeda Pharmaceuticals
FDA application	NDA 021925
Therapeutic category	Type 2 diabetes mellitus
Administration	Once daily with the first main meal
Release technology	Conventional immediate release

Pioglitazone is a thiazolidinedione that improves insulin sensitivity through PPAR-gamma activation. Glimepiride is a sulfonylurea that increases pancreatic insulin secretion. The combination addresses complementary mechanisms but also combines the safety liabilities of both components, including weight gain, edema, hypoglycemia and, for pioglitazone, boxed-warning heart-failure risk.[1]

The product’s formulation is commercially important because it does not depend on an advanced delivery system. Duetact uses a conventional compressed tablet, reducing manufacturing complexity and making the product accessible to generic manufacturers with standard high-shear granulation, blending, compression and film-coating equipment.

What excipients are used in Duetact tablets?

The FDA prescribing information identifies conventional tablet and coating excipients for Duetact. The core formulation uses lactose monohydrate, hydroxypropyl cellulose, carboxymethylcellulose calcium and magnesium stearate. The film coating contains hypromellose, polyethylene glycol, titanium dioxide and talc.[1]

Excipient	Likely formulation function	Commercial relevance
Lactose monohydrate	Diluent and tablet-bulk agent	Low-cost, widely available; may create dairy-derived labeling and compatibility considerations
Hydroxypropyl cellulose	Binder and granulation aid	Supports tablet hardness and granule integrity
Carboxymethylcellulose calcium	Disintegrant	Promotes tablet breakup and active release
Magnesium stearate	Lubricant	Controls die-wall friction; excessive levels can slow dissolution
Hypromellose	Film-forming polymer	Provides coating integrity and appearance
Polyethylene glycol	Plasticizer	Improves coating flexibility
Titanium dioxide	Opacifier and color modifier	Supports visual uniformity and light protection
Talc	Anti-tacking and coating aid	Improves coating processability

The precise quantitative composition is not generally disclosed in the public prescribing information. Generic manufacturers can use different excipients if the finished product meets applicable quality, dissolution and bioequivalence requirements.

How does the Duetact excipient strategy affect generic development?

The excipient strategy creates a relatively accessible ANDA target. A generic developer does not need to reproduce every inactive ingredient or the exact manufacturing process. It must establish pharmaceutical equivalence and bioequivalence, comply with current good manufacturing practice, and demonstrate acceptable quality attributes under FDA requirements.[2]

Key development targets include:

1. Assay and content uniformity for both active ingredients.
2. Immediate-release dissolution for pioglitazone and glimepiride.
3. Tablet hardness and friability.
4. Stability under long-term and accelerated conditions.
5. Control of lubricant concentration and blending time.
6. Consistent coating weight and appearance.
7. Compatibility between the two active ingredients and the excipient matrix.

The formulation challenge is dose asymmetry. Each tablet contains a fixed 30 mg pioglitazone dose, while glimepiride is present at either 2 mg or 4 mg. The two ingredients differ substantially in dose, particle characteristics, aqueous solubility and pharmacokinetic behavior. Low-dose glimepiride requires effective blending and content-uniformity controls.

A generic manufacturer can retain the reference-style excipient system to reduce development risk. It can also substitute excipients to improve flow, reduce tablet weight, remove lactose, or strengthen supply-chain resilience. The commercial value of substitution is limited if the change introduces dissolution variability or requires extensive formulation bridging.

What formulation opportunities exist for Duetact generics?

Lactose-free and diabetes-friendly excipient platforms

A lactose-free Duetact equivalent could use microcrystalline cellulose, mannitol, dibasic calcium phosphate or another suitable diluent. This may support procurement flexibility and address lactose-intolerance or formulation-preference concerns. It would not create a strong clinical differentiator by itself because lactose content in a conventional tablet is usually low.

The commercial benefit is strongest where a manufacturer has an established lactose-free platform across multiple oral solid products. Shared excipient sourcing can reduce inventory complexity and improve manufacturing utilization.

Direct-compression formulations

Duetact’s low-dose glimepiride component makes content uniformity the central issue in direct compression. A direct-compression approach could reduce processing steps, solvent use and granulation costs. It would require excipient grades with strong flow and segregation control.

A practical platform could combine a high-functionality diluent, a superdisintegrant and a low-level lubricant. The developer would need to demonstrate that the formulation preserves rapid release for both active ingredients. Direct compression is most attractive for manufacturers with high-volume tableting capacity and mature in-process controls.

Moisture- and oxygen-controlled formulations

A conventional film coat can provide handling and identification benefits but is not necessarily a high-barrier system. A manufacturer could explore moisture-barrier packaging, desiccant-supported bottles or higher-barrier blister systems rather than materially changing the tablet core.

The most efficient commercial solution may be packaging optimization. It can improve stability without increasing tablet manufacturing complexity or creating a new dosage-form profile.

Modified-release or once-daily reformulations

Duetact is already administered once daily. A modified-release reformulation therefore has limited adherence value. A new release profile could also create new pharmacokinetic and regulatory requirements without addressing the core safety concerns associated with pioglitazone and glimepiride.

A modified-release product would be a 505(b)(2) or new drug strategy rather than a conventional generic substitution. Its commercial rationale would need to rely on a measurable clinical benefit, such as reduced hypoglycemia or improved tolerability. The existing Duetact platform does not provide an obvious formulation-based route to that outcome.

What is the FDA regulatory status of Duetact?

Duetact was approved by FDA in 2006 under NDA 021925.[1] It is an approved fixed-dose combination for patients already treated with both pioglitazone and glimepiride or for patients requiring additional glycemic control after inadequate response to monotherapy.

The principal regulatory constraints are:

• Pioglitazone’s boxed warning regarding congestive heart failure.
• Contraindication in patients with established New York Heart Association Class III or IV heart failure.
• Hypoglycemia risk from glimepiride.
• Weight gain and edema.
• Bladder-cancer warnings and precautions associated with pioglitazone labeling.
• Need to align labeling with current FDA safety language.

A generic applicant must match the reference product’s active ingredients, strength, dosage form, route and labeling framework, subject to FDA-approved differences. Excipients can differ, but the finished dosage form cannot create clinically meaningful differences in performance or safety.

What patents protect Duetact and when does exclusivity end?

The commercial exclusivity associated with the original pioglitazone and glimepiride compounds has expired. Duetact therefore operates in a mature small-molecule market rather than a protected innovator market.

The relevant IP categories are:

IP category	Strategic position
Composition of matter	Expired for the underlying active ingredients
Fixed-dose combination	Historical combination protection may have existed, but it does not create a current broad market barrier
Tablet formulation	Conventional formulation offers limited defensibility
Method of use	Diabetes-treatment claims face narrow practical value after core exclusivity
Manufacturing process	Potentially protectable, but unlikely to block routine generic manufacture
Trade secrets	Process parameters, blend order and coating controls may remain confidential

Orange Book-listed patents and exclusivity should be checked against the current FDA publication before a filing or launch decision. The commercial conclusion is clear: Duetact is a generic-access opportunity, not a product dependent on continuing branded patent protection.[3]

Are Paragraph IV challenges and generic entry risks material?

Paragraph IV risk is historically relevant for Duetact because generic applicants may challenge any remaining listed patents as invalid, unenforceable or not infringed. The practical risk today is less about blocking patents and more about the economics of filing.

Potential generic entry scenarios include:

Scenario	Timing profile	Commercial effect
Single ANDA launch	First approved generic enters after approval and applicable exclusivity	Moderate price erosion
Multiple ANDA launches	Several manufacturers enter	Rapid price compression
Authorized generic	Brand-linked or license-backed generic enters	Faster share loss for independent generics
Low-volume niche launch	One supplier maintains limited distribution	Stable but modest opportunity
No launch despite approval	Market unattractive because of low volume or reimbursement	Patent clearance does not guarantee commercialization

The main generic-entry risks are low market growth, limited demand for sulfonylurea therapy, payer substitution, and competition from newer agents such as DPP-4 inhibitors, GLP-1 receptor agonists and SGLT2 inhibitors.

Which companies are likely to compete in the Duetact market?

Competition is likely to come from generic manufacturers with established diabetes portfolios, contract development and manufacturing organizations, and suppliers of pioglitazone and glimepiride as separate tablets.

The most credible competitors are companies that already have:

• FDA-approved oral solid diabetes products.
• Access to pioglitazone and glimepiride active pharmaceutical ingredients.
• Validated content-uniformity systems for low-dose drugs.
• Existing distribution into retail, mail-order and government channels.
• The ability to manufacture both 30 mg/2 mg and 30 mg/4 mg strengths.

Separate-component substitution is a major commercial constraint. Physicians and pharmacists can use pioglitazone and glimepiride tablets independently, allowing dose adjustment that the fixed-dose product cannot provide. Duetact’s value is therefore concentrated in convenience, prescription simplification and adherence.

How attractive is Duetact for licensing and contract manufacturing?

Duetact is more attractive as a portfolio-extension product than as a standalone licensing asset. A licensee could use it to fill a diabetes-product gap, add a fixed-dose combination to an established pioglitazone portfolio, or serve markets where low-cost oral therapy remains important.

The best licensing structures would emphasize:

• Territory-specific registration rights.
• Supply agreements with minimum purchase commitments.
• Dual sourcing for both active ingredients.
• Shared ownership of formulation improvements.
• Price-adjustment mechanisms for API and excipient costs.
• Regulatory support for strength-specific submissions.

A contract manufacturer can create value through a common platform for Duetact, pioglitazone and glimepiride tablets. The main cost advantage would come from shared raw-material qualification, common compression equipment and consolidated packaging operations.

What manufacturing and IP barriers remain?

The manufacturing barriers are operational rather than patent-driven. Important controls include low-dose glimepiride distribution, prevention of cross-contamination, lubricant optimization, blend uniformity, dissolution reproducibility and stability.

Potentially protectable improvements include:

• A validated low-segregation blend process.
• A lactose-free or low-weight tablet platform.
• Moisture-barrier packaging.
• Improved coating process controls.
• A manufacturing process that reduces tablet defects or improves yield.

These improvements may support process patents or trade-secret protection, but they are unlikely to prevent competitors from commercializing a therapeutically equivalent tablet.

How does Duetact compare with newer diabetes combinations?

Product type	Main advantage over Duetact	Main disadvantage
Duetact	Low-cost, once-daily fixed-dose therapy	Hypoglycemia, weight gain and pioglitazone safety concerns
Pioglitazone plus separate glimepiride	Flexible dose adjustment	More tablets and potentially lower adherence
Metformin combinations	Strong first-line positioning and broad use	Gastrointestinal tolerability issues
SGLT2 inhibitor combinations	Cardiovascular and renal outcome positioning for some agents	Higher cost and class-specific safety concerns
GLP-1 receptor agonists	Weight-loss and glycemic efficacy advantages	Injectable or higher-cost oral products
DPP-4 inhibitor combinations	Low hypoglycemia risk and convenient dosing	Higher cost and variable outcome advantages

Duetact’s competitive position depends primarily on price and access. Its formulation does not provide a meaningful technical moat against newer products.

What are the commercial opportunities for Duetact excipients?

The most credible opportunities are:

1. Low-cost generic tablets using the reference-style excipient system.
2. Lactose-free versions for manufacturers with a broader specialty portfolio.
3. Direct-compression platforms that reduce processing cost.
4. High-barrier packaging for stability-sensitive distribution channels.
5. Regional supply of qualified excipient systems to generic manufacturers.
6. Contract manufacturing using shared pioglitazone and glimepiride equipment.
7. Private-label or authorized-generic distribution in price-sensitive markets.
8. Dual-strength production with common tooling and packaging components.

Excipient suppliers should compete on validated functionality, supply reliability and regulatory documentation rather than novel chemistry. The product’s mature status makes switching cost, regulatory support and continuity of supply more valuable than premium excipient positioning.

Key Takeaways

• Duetact is an immediate-release tablet containing pioglitazone hydrochloride and glimepiride in 30 mg/2 mg and 30 mg/4 mg strengths.
• Its excipients are conventional and support a relatively low-complexity generic formulation.
• The main formulation challenge is uniform distribution of the low-dose glimepiride component.
• Generic opportunities are strongest in cost-efficient manufacture, dual-strength supply and regional distribution.
• A lactose-free or direct-compression formulation may offer operational benefits but limited clinical differentiation.
• Modified-release development has weak commercial logic because Duetact is already once daily.
• Current market barriers are commercial and clinical, not primarily patent-based.
• Separate-component substitution and newer diabetes therapies limit long-term demand.
• Excipient suppliers can create value through validated platforms, supply resilience and manufacturing efficiency.

FAQs

Is Duetact a combination product or a single active drug?

Duetact is a fixed-dose combination containing two active ingredients: pioglitazone hydrochloride and glimepiride.

Can a generic Duetact tablet use different excipients?

Yes. A generic may use different inactive ingredients if it meets FDA requirements for pharmaceutical equivalence, quality, dissolution, stability and bioequivalence.

Which Duetact strength has the greater formulation challenge?

The 30 mg/2 mg strength presents the greater content-uniformity challenge because glimepiride is present at a lower dose.

Is a lactose-free Duetact formulation commercially differentiated?

It may provide procurement and patient-preference benefits, but lactose-free status alone is unlikely to support a substantial price premium.

Does Duetact have meaningful biosimilar risk?

No. Duetact is a conventional small-molecule drug, so the relevant competitive pathway is generic substitution through ANDA approval, not biosimilar development.

References

1. U.S. Food and Drug Administration. (2023). Duetact (pioglitazone hydrochloride and glimepiride) prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

3. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.